🚀 VC round data is live in beta, check it out!
Rohto Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rohto Pharmaceutical and similar public comparables like Proya Cosmetics, Procter & Gamble Hygiene, e.l.f. Beauty, Giant Biogene and more.
Rohto Pharmaceutical Overview
About Rohto Pharmaceutical
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
Founded
1949
HQ
Employees
10.9K
Website
Financials (LTM)
EV
$3B
Rohto Pharmaceutical Financials
Rohto Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $355M.
In the same LTM period, Rohto Pharmaceutical generated $1B in gross profit, $355M in EBITDA, and $215M in net income.
Revenue (LTM)
Rohto Pharmaceutical P&L
In the most recent fiscal year, Rohto Pharmaceutical reported revenue of $2B and EBITDA of $356M.
Rohto Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $355M | XXX | $356M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $215M | XXX | $212M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rohto Pharmaceutical Stock Performance
Rohto Pharmaceutical has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Rohto Pharmaceutical's stock price is $15.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.1% | XXX | XXX | XXX | $0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRohto Pharmaceutical Valuation Multiples
Rohto Pharmaceutical trades at 1.6x EV/Revenue multiple, and 9.6x EV/EBITDA.
EV / Revenue (LTM)
Rohto Pharmaceutical Financial Valuation Multiples
As of April 11, 2026, Rohto Pharmaceutical has market cap of $4B and EV of $3B.
Equity research analysts estimate Rohto Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rohto Pharmaceutical has a P/E ratio of 16.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 12.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | 16.6x | XXX | 16.8x | XXX | XXX | XXX |
| EV/FCF | 24.1x | XXX | 20.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rohto Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Rohto Pharmaceutical Margins & Growth Rates
Rohto Pharmaceutical's revenue in the last 12 month grew by 6%.
Rohto Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Rohto Pharmaceutical's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rohto Pharmaceutical's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Rohto Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (0%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Rohto Pharmaceutical Public Comps
See public comps and valuation multiples for other Health & Beauty and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Proya Cosmetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Hygiene | XXX | XXX | XXX | XXX | XXX | XXX |
| e.l.f. Beauty | XXX | XXX | XXX | XXX | XXX | XXX |
| Giant Biogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Hengan Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rohto Pharmaceutical M&A Activity
Rohto Pharmaceutical acquired XXX companies to date.
Last acquisition by Rohto Pharmaceutical was on XXXXXXXX, XXXXX. Rohto Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Rohto Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRohto Pharmaceutical Investment Activity
Rohto Pharmaceutical invested in XXX companies to date.
Rohto Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Rohto Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Rohto Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rohto Pharmaceutical
| When was Rohto Pharmaceutical founded? | Rohto Pharmaceutical was founded in 1949. |
| Where is Rohto Pharmaceutical headquartered? | Rohto Pharmaceutical is headquartered in Japan. |
| How many employees does Rohto Pharmaceutical have? | As of today, Rohto Pharmaceutical has over 10K employees. |
| Who is the CEO of Rohto Pharmaceutical? | Rohto Pharmaceutical's CEO is Kunio Yamada. |
| Is Rohto Pharmaceutical publicly listed? | Yes, Rohto Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Rohto Pharmaceutical? | Rohto Pharmaceutical trades under 4527 ticker. |
| When did Rohto Pharmaceutical go public? | Rohto Pharmaceutical went public in 1962. |
| Who are competitors of Rohto Pharmaceutical? | Rohto Pharmaceutical main competitors are Proya Cosmetics, Procter & Gamble Hygiene, e.l.f. Beauty, Giant Biogene. |
| What is the current market cap of Rohto Pharmaceutical? | Rohto Pharmaceutical's current market cap is $4B. |
| What is the current revenue of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months revenue is $2B. |
| What is the current revenue growth of Rohto Pharmaceutical? | Rohto Pharmaceutical revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Rohto Pharmaceutical? | Current revenue multiple of Rohto Pharmaceutical is 1.6x. |
| Is Rohto Pharmaceutical profitable? | Yes, Rohto Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months EBITDA is $355M. |
| What is Rohto Pharmaceutical's EBITDA margin? | Rohto Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Rohto Pharmaceutical? | Current EBITDA multiple of Rohto Pharmaceutical is 9.6x. |
| What is the current FCF of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months FCF is $142M. |
| What is Rohto Pharmaceutical's FCF margin? | Rohto Pharmaceutical's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Rohto Pharmaceutical? | Current FCF multiple of Rohto Pharmaceutical is 24.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.